News
Read the latest from M8.
Sep 20, 2023
Acino Significantly Expands Presence and Capabilities in Latin America Through Acquisition of M8 Pharmaceuticals
Aug 01, 2023
M8 Pharmaceuticals obtains market authorization for Barlo® (Carragelose®) nasal spray in Mexico
Feb 28, 2023
M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavogliflozin) for Brazil and Mexico
Oct 03, 2022
moksha8 officially rebrands as M8 Pharmaceuticals
May 05, 2022
M8 Pharmaceuticals Announces approval of Mokbio® PS128™ in Mexico
Oct 05, 2021
M8 Pharmaceuticals Announces License of Exclusive Mexican Rights for Arlevert® from HENNIG ARZNEIMITTEL
Sep 14, 2021
M8 Pharmaceuticals Announces License of Exclusive rights for Diacomit® (Stiripentol) from Biocodex SAS
Aug 31, 2021
M8 Pharmaceuticals Announces License of Exclusive rights MED3000 from Futura Medical for Latin America
Partner with Us
From go-to-market strategy and registration to access and long-term market presence, M8 is a purpose-built biopharmaceutical platform that supports the entire development-commercialization continuum.
Work with Us
Our motivated team fosters a supportive and positive culture fueled by the will to bring value to the patients of Latin America.
moksha8 Pharmaceuticals and Daewoong Pharmaceuticals sign exclusive licensing agreement to commercialize Nabota (botulinum toxin) in Brazil
Jan 29, 2018
moksha8 Pharmaceuticals, announced today that it has entered into an exclusive licensing agreement with Daewoong Pharmaceuticals to commercialize botulinum toxin product Nabota in Brazil, the largest economy in Latin America.
“We are honored to be partnering with Daewoong Pharmaceuticals, one of the leading research- based companies in the world, in order to help expand the usage of Nabota in Latin America", said Joel Barlan.
Under the new agreement, moksha8 will be responsible for marketing authorizations, market access, commercialization, distribution throughout Brazil.
moksha8 Brazil will adopt a two-track marketing strategy for Nabota, the company will be in charge of Nabota applied to medical conditions while cosmetic use will be taken care of by GC Aesthetic Brazil, the leading pure play female Aesthetic company.